ACRA BIO-B
$729.86 0.0000 0.0000%
Today share price
USA
Sector: Healthcare Industry: Medical Devices
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 28 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

20.82B
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

21.65B
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.

0.89
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.

28.52M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.

-

Upcoming events

All events
No upcoming events scheduled

Stock chart

Stock analysis

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
-64.58 3.76
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
2.38 3.66
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
44.39 2.07
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
1.71 -
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
-3.56 5.05

Price change per year

515.00$ 818.60$
Min Max

Summary analysis

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure

Revenue and net income

All parameters

Stock news

All news

Россия отгрузит из портов на западе страны в мае 8,5 млн т нефти - источники

Компания "Ташир" стала инвестором для восстановления форта в Кронштадте

Рубль существенно вырос благодаря накопившейся выручке, динамике FX и нефти

ПУТИН И ПРЕЗИДЕНТ БОЛИВИИ ОБСУДИЛИ РЕАЛИЗАЦИЮ ВЗАИМОВЫГОДНЫХ СОВМЕСТНЫХ ПРОЕКТОВ В ТОРГОВО-ЭКОНОМИЧЕСКОЙ И ЭНЕРГЕТИЧЕСКОЙ ОБЛАСТЯХ - КРЕМЛЬ

Путин и президент Боливии обсудили развитие двусторонних отношений - Кремль

Власти Аргентины объявят чрезвычайное положение в сфере железнодорожного транспорта

US STOCKS-Уолл-стрит в плюсе, рынки ждут инфляционных данных США

РФ ОТГРУЗИТ ИЗ ЗАПАДНЫХ ПОРТОВ В МАЕ 8,5 МЛН Т НЕФТИ (9,5 МЛН Т В АПРЕЛЕ) - ИСТОЧНИКИ, РАСЧЕТ РЕЙТЕР

РАСХОДЫ БЮДЖЕТА РФ НА НАЦПРОЕКТЫ НА 1 МАЯ ПРЕДВАРИТЕЛЬНО СОСТАВИЛИ 1,124 ТРЛН РУБ. ИЛИ 37% ОТ ПЛАНОВЫХ НАЗНАЧЕНИЙ - МИНФИН

Расходы бюджета РФ на нацпроекты на 1 мая составили 1,124 трлн руб. - Минфин

ЦБР пока не готов судить однозначно, требуется снижение или повышение ставки - резюме обсуждения

TREASURIES-Доходность UST в минусе, инвесторы ожидают данных об инфляции

ЧЛЕНЫ СД ЦБР СОГЛАСИЛИСЬ, ЧТО ОЖИДАЕМОГО ЗАМЕДЛЕНИЯ КРЕДИТОВАНИЯ НЕ ПРОИСХОДИТ, НО СБЕРЕГАТЕЛЬНАЯ АКТИВНОСТЬ ОСТАЕТСЯ ВЫСОКОЙ

ЧЛЕНЫ СОВЕТА ДИРЕКТОРОВ ЦБР В АПРЕЛЕ РАССМОТРЕЛИ ДВА ВАРИАНТА РЕШЕНИЯ: СОХРАНЕНИЕ СТАВКИ НА УРОВНЕ 16,00% И ПОВЫШЕНИЕ НА 100 Б.П. ДО 17,00%

СПЕКТР ВАРИАЦИЙ БАЗОВОГО СЦЕНАРИЯ ПРЕДПОЛАГАЛ КАК ВОЗМОЖНОСТЬ НАЧАЛА СНИЖЕНИЯ СТАВКИ ВО 2 ПОЛ 24Г, ТАК И СОХРАНЕНИЕ ЕЕ НЕИЗМЕННОЙ ДО КОНЦА ГОДА

ЦБР ИСХОДИТ ИЗ НЕИЗМЕННОЙ ТРАЕКТОРИИ НОРМАЛИЗАЦИИ БЮДЖЕТНОЙ ПОЛИТИКИ, ПОЛНОГО ФИНАНСИРОВАНИЯ ДОПРАСХОДОВ ЗА СЧЕТ УВЕЛИЧЕНИЯ НАЛОГОВЫХ ПОСТУПЛЕНИЙ

ЧЛЕНЫ СД ЦБР В АПРЕЛЕ ДИСКУТИРОВАЛИ О СКОРОСТИ ДЕЗИНФЛЯЦИИ, МНОГИЕ ВИДЯТ ФАКТОРЫ, СПОСОБНЫЕ ЗАМЕДЛИТЬ СНИЖЕНИЕ ИНФЛЯЦИИ - РЕЗЮМЕ ОБСУЖДЕНИЯ

BHP: Anglo American отклонила пересмотренное предложение в $42,7 млрд

НАРАСТАНИЕ НАПРЯЖЕННОСТИ НА РЫНКЕ ТРУДА УКАЗЫВАЕТ НА СОХРАНЕНИЕ ЗНАЧИТЕЛЬНОГО ПОЛОЖИТЕЛЬНОГО РАЗРЫВА ВЫПУСКА - ЦБР

Майские заморозки не оказали существенного влияния на бизнес ГК "Русагро" - компания

About company

Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Address:
1000 Alfred Nobel Drive, Hercules, CA, United States, 94547
Company name:
Issuer ticker: BIO-B
ISIN: US0905721082
Country: USA
Exchange: ACRA
Currency: $
IPO date: 1999-09-21
Sector: Healthcare
Industry: Medical Devices
Site: https://www.bio-rad.com

On which stock exchange are (BIO-B) stocks traded?

(BIO-B) stocks are traded on ACRA.

What is the ticker of stocks (BIO-B)?

The stock ticker of ’s stocks or in other words, the code is BIO-B. The stocks are currently listed on the ACRA exchange.

In which sector and industry does (BIO-B) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, (BIO-B) belongs to the «Healthcare» sector and the «Medical Devices» industry.

In what currency are (BIO-B) stocks traded?

(BIO-B) stocks are traded on the ACRA exchange in dollars.

What is the price of (BIO-B) stocks today?

The current price of stocks on 13.05.2024 is 729.86 dollars. per share.

What is the dynamics of (BIO-B) stocks from the beginning of the year?

(BIO-B) quotes have increased by 0% from the beginning of the year up to 729.86 dollars. per 1 stocks.

How much did (BIO-B) stocks increase in мае 2024?

This month (BIO-B) quotes have increased by 0% to 729.86 dollars. per share.

How much are (BIO-B) stocks worth?

Today, on October, 13.05.2024 ’s (BIO-B) stocks cost 729.86 dollars..

What is the market capitalization of (BIO-B)?

Capitalization is the market value of (BIO-B) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 13.05.2024, the market capitalization of (BIO-B) is estimated at about 20818483578 dollars.